Gapping down
In reaction to disappointing earnings/guidance:
- REVG -18.5%, ATU -10%, PIR -9.9%, CAG -5.5%, LMNR -5%, ACN -2.5%, WBA -2.1%, SAFM -1.5%, .
Select oil/gas related names showing weakness with oil down 3%:
- MRO -2.53% SWN -2.23% WLL -1.80% CVE -1.73% OXY -1.51% OAS -1.33% MPLX -1.25% CRZO -1.21% PXD -1.18%
Other news:
- DBVT -45.9% (withdraws BLA for Viaskin Peanut following discussions with FDA regarding insufficient data)
- ADMA -43% (provides BIVIGAM PAS Submissions update -- FDA issued Complete Response Letter for Prior Approval Supplement drug substance, approves PAS for drug product),
- SPPI -34.9% (FDA did not grant Breakthrough Therapy Designation to poziotinib)
- GTHX -27.1% (top-line results from randomized phase 2 Trial of Trilaciclib showing multi-lineage myelopreservation benefits in 2nd-/3rd-line small cell lung cancer)
- MNKD -17.2% (sold 26.7M stock/warrants at $1.50/share)
Analyst comments:
- EB -1.9% (downgraded to Hold at Stifel)